Copyright
©The Author(s) 2022.
World J Clin Cases. Apr 6, 2022; 10(10): 3047-3059
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3047
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3047
Table 2 Laboratory findings of the patient cohort
| Variable | All patients (N = 325) | Survivor non-survivor (n = 308); (n = 17) | P value | |
| Laboratory findings | ||||
| White-cell count (109/L) | 4.6 (3.3-6.0) | 4.6 (3.29-5.9) | 6.4 (3.6-7.4) | 0.090 |
| Red-cell count (1012/L) | 4.3 (4.1-4.7) | 4.3 (4.1-4.7) | 4.2 (4.0-4.6) | 0.557 |
| Hemoglobin (g/L) | 131.0 (120.0-142.0) | 131.0 (121.0-142.5) | 130.0 (114.0-141.0) | 0.360 |
| Platelet count (109/L) | 171.0 (134.0-202.0) | 173.0 (136.0-204.5) | 143.0 (119.0-155.0) | 0.0081 |
| Hematocrit (%) | 39.4 (36.5-42.6) | 39.4 (36.6-42.6) | 40.0 (34.6-42.6) | 0.530 |
| Neutrophil percentage (%) | 64.6 (56.8-75.5) | 64.5 (56.4-75.2) | 73.4 (67.3-81.8) | 0.0071 |
| Lymphocyte percentage (%) | 26.5 ± 14.5 | 26.6 ± 12.3 | 18.6 (11.2-22.5) | 0.0081 |
| Monocyte percentage (%) | 7.9 ± 3.5 | 8.1 ± 3.5 | 6.2 (3.4-6.9) | 0.0081 |
| Eosinophil percentage (%) | 0.1 (0.0-0.6) | 0.1 (0.0-0.55) | 0.0 (0.0-0.8) | 0.953 |
| Basophil percentage (%) | 0.2 (0.1-0.3) | 0.2 (0.1-0.3) | 0.2 (0.1-0.3) | 0.946 |
| Mean red blood cell volume (fL) | 90.6 (87.5-93.6) | 90.6 (87.6-93.6) | 88.9 (85.7-93.1) | 0.432 |
| Mean hemoglobin content (pg) | 30.0 (28.8-31.1) | 30.0 (28.9-31.1) | 29.4 (27.5-30.5) | 0.209 |
| Mean hemoglobin concentration (g/L) | 330.0 (323.0-336.0) | 330.0 (323.0-336.0) | 324.0 (321.0-331.0) | 0.0291 |
| RBC distribution width standard deviation (%) | 39.4 (36.7-41.2) | 39.2 (36.5-41.2) | 40.7 (37.5-42.8) | 0.071 |
| RBC distribution width-coefficient of variation (%) | 12.7 (12.2-14.4) | 12.7 (12.1-14.1) | 13.3 (12.6-15.4) | 0.116 |
| Neutrophil count (109/L) | 2.96 (1.92-4.05) | 2.9 (1.9-4.0) | 4.1 (2.7-4.9) | 0.0351 |
| Lymphocyte count (109/L) | 1.13 ± 0.55 | 1.14 ± 0.55 | 0.89 ± 0.58 | 0.0351 |
| Monocyte count (109/L) | 0.34 (0.24-0.46) | 0.3 (0.3-0.5) | 0.3 (0.2-0.5) | 0.828 |
| Eosinophil count (109/L) | 0.01 (0.0-0.02) | 0.01 (0.0-0.02) | 0.0 (0.0-0.06) | 0.642 |
| Basophil count (109/L) | 0.01 (0.01-0.02) | 0.01 (0.01-0.02) | 0.01 (0.01-0.02) | 0.060 |
| Platelet distribution width (%) | 12.5 (10.6-16.2) | 12.5 (10.6-16.2) | 15.1 (10.9-16.4) | 0.452 |
| Large platelet ratio (%) | 11.1 (9.8-21.2) | 11.1 (9.8-21.4) | 10.0 (10.0-12.9) | 0.405 |
| Mean platelet volume (fL) | 19.0 (10.0-28.7) | 18.5 (9.9-27.9) | 28.9 (18.8-32.4) | 0.0181 |
| Platelet hematocrit (%) | 0.17 (0.14-0.20) | 0.17 (0.14-0.20) | 0.13 (0.13-0.16) | 0.0161 |
| Distribution of other findings-no./total no. (%) | ||||
| Systolic blood pressure (mmHg) | 123.6 ± 13.6 | 123.0 ± 12.7 | 135.4 ± 21.0 | 0.0221 |
| Diastolic blood pressure (mmHg) | 76.4 ± 9.5 | 76.4 ± 9.3 | 76.2 ± 13.1 | 0.464 |
| Blood glucose concentration (mmol/L) | 6.4 ± 2.6 | 6.2 ± 2.3 | 9.1 ± 4.8 | 0.0091 |
| Total cholesterol (mmol/L) | 3.8 (3.2-4.5) | 3.9 (3.3-4.5) | 2.7 (2.6-3.3) | 0.0031 |
| Triglyceride (mmol/L) | 1.1 (0.8-1.4) | 1.1 (0.8-1.4) | 0.9 (0.8-1.0) | 0.455 |
| High density lipoprotein (mmol/L) | 1.1 (0.9-1.2) | 1.1 (0.9-1.3) | 0.97 (0.94-1.12) | 0.354 |
| Low density lipoprotein (mmol/L) | 2.2 ± 0.7 | 2.2 ± 0.7 | 1.5 ± 0.6 | 0.0021 |
| C-reactive protein (mg/dL) | 1.3 (0.3-3.4) | 1.3 (0.3-3.0) | 5.9 (3.3-8.2) | < 0.0011 |
| Lactate dehydrogenase (U/L) | 178.5 (137.5-236.5) | 173.0 (136.0-229.0) | 275.0 (232.0-324.0) | < 0.0011 |
| Aspartate aminotransferase (U/L) | 22.2 (17.1-32.8) | 21.7 (16.8-32.3) | 31.2 (25.5-36.5) | 0.0191 |
| Alanine aminotransferase (U/L) | 19.1 (12.8-32.6) | 18.9 (12.7-33.2) | 19.9 (15.5-29.7) | 0.957 |
| γ–Glutamyltransferase (U/L) | 19.0 (12.6-38.2) | 19.0 (12.4-38.0) | 27.8 (16.9-69.0) | 0.064 |
| Blood urea nitrogen (mmol/L) | 4.1 (3.2-5.3) | 4.0 (3.2-5.0) | 6.4 (5.3-11.1) | < 0.0011 |
| Creatine kinase (ng/mL) | 76.5 (45.0-140.0) | 77.1 (45.0-138.0) | 74.0 (61.0-203.0) | 0.404 |
| Creatinine (μmol/L) | 63.9 (53.6-76.7) | 63.0 (53.1-74.7) | 83.7 (74.9-254.2) | < 0.0011 |
| α-Hydroxybutyrate dehydrogenase (U/L) | 137.5 (109.0-176.5) | 135.0 (108.0-171.0) | 208.0 (158.0-217.0) | 0.0011 |
| D-dimer (μg/mL) | 0.4 (0.2-0.8) | 0.4 (0.2-0.8) | 1.1 (0.6-6.3) | < 0.0011 |
| Procalcitonin (ng/mL) | 0.05 (0.04-0.09) | 0.05 (0.03-0.08) | 0.3 (0.1-2.8) | < 0.0011 |
| Brain Natriuretic peptide (pg/mL) | 34.4 (13.0-128.0) | 31.6 (12.0-108.0) | 295.8 (177.0-406.1) | < 0.0011 |
| Antihypertensive drugs | < 0.0011 | |||
| Yes | 57 (17.5) | 47 (14.5) | 10 (3.0) | |
| No | 268 (82.5) | 261 (80.3) | 7 (2.2) | |
| Hypoglycemic drugs | < 0.0011 | |||
| Yes | 28 (8.6) | 22 (6.8) | 6 (1.8) | |
| No | 297 (91.4) | 286 (88) | 11 (3.4) | |
| Lipid-lowering drugs | 0.0051 | |||
| Yes | 14 (4.3) | 11 (3.4) | 3 (0.9) | |
| No | 311 (95.7) | 297 (91.4) | 14 (4.3) | |
- Citation: Zhao SC, Yu XQ, Lai XF, Duan R, Guo DL, Zhu Q. Dose-response relationship between risk factors and incidence of COVID-19 in 325 hospitalized patients: A multicenter retrospective cohort study. World J Clin Cases 2022; 10(10): 3047-3059
- URL: https://www.wjgnet.com/2307-8960/full/v10/i10/3047.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i10.3047